Efficacy and Safety of Two Artificial Tears in Patients with Mild to Moderate Dry Eye Symptoms

Introduction

Dry eye syndrome is the most common ophthalmic manifestation and increases the risk of ocular infection, corneal ulcer, and blindness

Aim

To compare the efficacy and safety of two preservative-free lubricant eye drops; Osmodrops (carboxymethylcellulose 0.5%, glycerin 0.9%; Cipla Ltd.) and OptiveTM (carboxymethyl cellulose 0.5%; Allergan Inc.) in patients with mild to moderate DED

Patient Profile

  • 178 patients with mild to moderate DED (Dry Eye severity level 2 as per Dry Eye Workshop II grading system)

Methods

  • Prospective, randomized study
  • Patients were randomized to receive either Osmodrops or Optive 4 times daily dosing for a duration of 8 weeks
  • Ocular Surface Disease Index (OSDI), tear break-up time (TBUT), corneal fluorescein staining
  • Baseline, 4 weeks, 8 weeks

Results

Figure 1: Improvement in OSDI with Osmodrops & Optive after 8 weeks (P<0.001)

Figure 2: Improvement in TBUT with Osmodrops & Optive after 8 weeks (P<0.001)

Figure 3: Improvement in Corneal staining with Osmodrops & Optive after 8 weeks (P<0.001)

Conclusion

Both eye drops were found to be effective in decreasing the OSDI score and improving the tear film stability in patients with mild to moderate dry eye symptoms

Reference

European Journal of Biomedical and Pharmaceutical Sciences. 2019; 6; 11:78-86